Valuation: Aligos Therapeutics, Inc.

Market Cap 32.72M 28.53M 26.94M 24.47M 45.84M 3.14B 46.03M 323M 125M 1.6B 123M 120M 5.14B P/E 2026 *
-0.81x
P/E 2027 * -0.98x
Enterprise Value -885K -771K -728K -661K -1.24M -84.87M -1.24M -8.72M -3.37M -43.15M -3.32M -3.25M -139M EV / Sales 2026 *
-0.02x
EV / Sales 2027 * -57.1x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day+1.35%
1 week+0.38%
Current month-10.58%
1 month-22.49%
3 months-0.76%
6 months-24.60%
Current year-43.78%
1 week 4.82
Extreme 4.82
5.44
1 month 4.82
Extreme 4.82
7.72
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Free

Chief Technology Officer

23,310 0.4354%
9/3/26 Free

Controller/Auditor

9,450 0.1765%
9/3/26 Free

Chief Executive Officer

105,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
+1.35%+0.38%-47.55%-73.80% 32.72M
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -0.76%+3.42%+40.31%+96.38% 26.24B
Weighted average by Cap. -1.02%+1.87%+64.68%+130.20%

Financials

2026 *2027 *
Net sales 35.99M 31.39M 29.64M 26.91M 50.42M 3.45B 50.63M 355M 137M 1.76B 135M 132M 5.65B 4.65M 4.05M 3.83M 3.48M 6.51M 446M 6.54M 45.86M 17.7M 227M 17.47M 17.08M 730M
Net income -79.34M -69.19M -65.33M -59.32M -111M -7.61B -112M -783M -302M -3.87B -298M -291M -12.45B -125M -109M -103M -93.38M -175M -11.98B -176M -1.23B -475M -6.09B -469M -459M -19.6B
Net Debt -33.61M -29.3M -27.67M -25.13M -47.08M -3.22B -47.27M -331M -128M -1.64B -126M -123M -5.28B -298M -260M -246M -223M -418M -28.61B -419M -2.94B -1.13B -14.55B -1.12B -1.1B -46.81B
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
18/09/26 US$5.240 +1.35% 21,340
17/09/26 US$5.170 +2.38% 21,705
16/09/26 US$5.050 +1.20% 41,651
15/09/26 US$4.990 -0.99% 34,487
14/09/26 US$5.040 -3.45% 28,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.240USD
Average target price
52.38USD
Spread / Average Target
+899.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!